Skip to main content
REVELATION BIOSCIENCES, INC. logo

REVELATION BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · REVB ISIN · US7164211028 LEI · 549300UKS15BEXENY615 US Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2026-01-30 Capital/Financing Update
Country US United States of America
Listing US REVB

About REVELATION BIOSCIENCES, INC.

https://www.revbiosciences.com/

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic-based therapies for the prevention and treatment of disease. The company's core strategy involves rebalancing inflammation and harnessing the innate immune system to optimize health. Its lead product candidate, Gemini, is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®). Gemini is designed to reprogram the innate immune system to respond to stressors like trauma and infection in an attenuated manner, thereby reducing inflammation-associated damage. The company is evaluating Gemini for various applications, including the prevention of post-surgical infections and acute kidney injury.

Recent filings

Filing Released Lang Actions
S-3 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a preliminary prospectus for the resale of common stock shares by selling stockholders. The text references the Securities Act of 1933 and details about the offering, selling stockholders, and related legal and financial information. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is a full registration statement/prospectus filing.
2026-01-30 English
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text details a material definitive agreement regarding warrant exercise inducement offer letters, unregistered sales of equity securities, and related financial advisory agreements. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The content focuses on capital raising and financing activities through warrant exercises and issuance of new warrants. Therefore, the document fits the Capital/Financing Update (CAP) category, which covers updates on company fundraising and capital structure changes. The document length and detail support a high confidence in this classification.
2026-01-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 21, 2026. It announces a press release about an agreement with the FDA and the availability of an updated corporate presentation on the company's website. The document includes references to a press release and a corporate presentation as exhibits. The text explicitly states that the information is being furnished and not filed, and it does not contain detailed financial statements or substantive financial data. The document is short (4178 characters) and serves as an announcement of events and materials rather than the materials themselves. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2026-01-21 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-21 English
4
Director's Dealing
2026-01-12 English
4
Director's Dealing
2026-01-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.